

FOR IMMEDIATE RELEASE

Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces FY 2006 Third Quarter Results

ST. PAUL, MN – May 15, 2006 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the third quarter of fiscal year 2006 ended March 31, 2006.

Revenue for the quarter totaled \$571,988 compared to \$215,234 in the prior year's third quarter ended March 31, 2005, which represents a 166% increase. The Company incurred a net loss of \$276,031 for the quarter or \$(.01) per share compared with a net loss of \$356,454 for the prior year's quarter or \$(.01) per share. Included in the net loss of \$276,031 for the quarter are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of \$266,734. Included in the net loss of \$356,454 for the prior year's quarter are non-cash charges of \$86,523. The Company reported a cash balance of \$1,815,308 on March 31, 2006. Total tests transmitted, a key metric for gauging customer usage, was 8,653 for the quarter, a 72% increase from the prior year's quarterly transmissions.

For the nine month period ended March 31, 2006, total revenue was \$1,494,010, compared to \$760,670 for the same period one year ago, a 96% increase. For the nine month period ended March 31, 2006, the Company incurred a net loss of \$897,175, or \$(.03) per share, compared with a net loss of \$1,230,701, or \$(.05) per share, for the same period one year ago. Included in the net loss of \$897,175 for the nine months are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of \$584,225. Included in the net loss of \$1,230,701 for the prior year's nine months are total non-cash charges of 401,839.

"The Company continues to see triple digit comparable quarterly total revenue growth. The results for the current quarter are especially encouraging as our core domestic business increased over 40% from the second quarter, indicating strong sequential domestic quarterly revenue growth," said Mark N. Schwartz, Chairman and CEO.

The Company has scheduled a conference call to discuss its quarterly financial results on Monday, May 15th 2006, at 4:00 PM Central Time. To participate in the conference call, please call: 800-914-3396 and use conference code: 5661236#.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2005 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations (Unaudited)

	Three Months Ended March 31		Nine Months Ended March 31	
	2006	2005	2006	2005
Revenue:				
Equipment sales	\$ 457,328	\$ 25,145	\$ 1,142,986	\$ 157,865
Equipment rental	107,066	185,382	334,210	430,739
Service/contract income	7,594	4,707	16,814	172,066
	<u>571,988</u>	<u>215,234</u>	<u>1,494,010</u>	<u>760,670</u>
Cost of Sales	<u>26,471</u>	<u>27,772</u>	<u>88,964</u>	<u>127,060</u>
Gross Profit	<u>545,517</u>	<u>187,462</u>	<u>1,405,046</u>	<u>633,610</u>
Expenses:				
Selling, general and administrative	<u>831,318</u>	<u>553,541</u>	<u>2,332,666</u>	<u>1,886,431</u>
Total Expenses	<u>831,318</u>	<u>553,541</u>	<u>2,332,666</u>	<u>1,886,431</u>
Operating Loss	(285,801)	(366,079)	(927,620)	(1,252,821)
Other Income (Expense):				
Interest income	<u>9,770</u>	<u>9,625</u>	<u>30,445</u>	<u>22,120</u>
Net Loss	<u>\$ (276,031)</u>	<u>\$ (356,454)</u>	<u>\$ (897,175)</u>	<u>\$ (1,230,701)</u>
Basic and Diluted Net Loss per Share	\$ (.01)	\$ (.01)	\$ (.03)	\$ (.05)
Weighted Average Shares Outstanding	35,012,499	27,778,459	33,726,604	27,287,367

Balance Sheet Data

	<u>March 31, 2006</u>	<u>June 30, 2005</u>
	(Unaudited)	(Audited)
Cash and cash equivalents	\$ 1,815,308	\$ 1,525,865
Total current assets	2,321,957	1,962,747
Total assets	2,433,429	2,193,866
Total current liabilities	391,543	574,671
Accumulated deficit	(25,602,752)	(24,705,577)
Total shareholders' equity	2,031,781	1,603,537

#

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of
Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdii.com